In Vitro/in Vivo relationship of gabapentin from a sustained-release tablet formulation: A pharmacokinetic study in the beagle dog

Archives of Pharmacal Research

Volumn 31, Issue 7, 2008, Pages 911-917

  Rhee, Yun Seok ^a,b   Park, Seok ^b   Lee, Tae Won ^b   Park, Chun Woong ^a   Nam, Tae Young ^a   Oh, Tack Oon ^a   Jeon, Ji Woong ^a   Han, Sang Beom ^c   Lee, Dong Soo ^b   Park, Eun Seok ^a  

^a Sungkyunkwan University   (South Korea)

^b Whanin Pharm Co Ltd   (South Korea)

^c Chung Ang University   (South Korea)

Author keywords

Dog; Gabapentin; Pharmacokinetic; Sustained release

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE; ANTICONVULSIVE AGENT; CYCLOHEXANECARBOXYLIC ACID DERIVATIVE; GABAPENTIN;

ANIMAL; AREA UNDER THE CURVE; ARTICLE; CALIBRATION; DELAYED RELEASE FORMULATION; DOG; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; QUALITY CONTROL; REPRODUCIBILITY; SOLUBILITY;

AMINES; ANIMALS; ANTICONVULSANTS; AREA UNDER CURVE; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOHEXANECARBOXYLIC ACIDS; DELAYED-ACTION PREPARATIONS; DOGS; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; MALE; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SOLUBILITY;

EID: 49749089639     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-001-1246-x     Document Type: Article

References (39)

1. Akiyama, Y., Nagahara, N., Nara, E., Kitano, M., Iwasa, S., Yamamoto, I., Azuma, J., and Ogawa, Y., Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites. J. Pharm. Pharmacol., 50, 159-166 (1998).
2. Bechgaard, H. and Ladefoged, K., Distribution of pellets in the gastrointestinal tract. The influence on transit time exerted by the density or diameter of pellets. J. Pharm. Pharmacol., 30, 690-692 (1978).
3. Beydoun, A., Uthman, B. M., and Sackellares, J. C., Gabapentin: Pharmacokinetics, efficacy and safety. Clin. Neuropharmacol., 18, 469-481 (1995).
4. Bryans, J. S. and Wustrow, D. J., 3-substituted GABA analogs with central nervous system activity. Med. Res. Rev., 19, 149-177 (1999).
5. Cargill, R., Caldwell, L. J., Engle, K., Fix, J. A., Porter, P. A., and Gardner, C. R., Controlled gastric emptying. I. Effects of physical properties on gastric residence times of nondisintegrating geometric shapes in beagle dogs. Pharm. Res., 5, 533-536 (1988).
6. Castaneda-Hernandez, G., Caille, G., and du Souich, P., Influence of drug formulation on drug concentration-effect relationships. Clin. Pharmacokinet., 26, 135-143 (1994).
7. Cundy, K. C., Branch, R., Chernov-Rogan, T., Dias, T., Estrada, T., Hold, K., Koller, K., Liu, X., Mann, A., Panuwat, M., Raillard, S. P., Upadhyay, S., Wu, Q. Q., Xiang, J. N., Yan, H., Zerangue, N., Zhou, C. X., Barrett, R. W., and Gallop, M. A., XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion to gabapentin, and transport by intestinal solute transporters. J. Pharmacol. Exp. Ther., 311, 315-323 (2004a).
8. Cundy, K. C., Annamalai, T., Bu, L., De Vera, J., Estrela, J., Luo, W., Shirsat, P., Torneros, A., Yao, F., Zou, J., Barrett, R. W., and Gallop, M.A., XP13512 [(+/-)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1- cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J. Pharmacol. Exp. Ther., 311, 324-333 (2004b).
9. Davis, S. S., Stockwell, A. F., Taylor, M. J., Hardy, J. G., Whalley, D. R., Wilson, C. G., Bechgaard, H., and Christensen, F. N., The effect of density on the gastric emptying of single-and multiple-unit dosage forms. Pharm. Res., 3, 208-213 (1986).
10. Deshpande, A. A., Shah, N. H., Rhodes, C. T., and Malick, W., Development of a novel controlled-release system for gastric retention. Pharm. Res., 14, 815-819 (1997).
11. Fujioka, K., Pans, M., and Joyal, S., Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin. Ther., 25, 515-529 (2003).
12. Gidal, B. E., Radulovic, L. L., Kruger, S., Rutecki, P., Pitterle, M., and Bockbrader, H. N., Inter-and intra-subject variability in gabapentin absorption and absolute bioavailability. Epilepsy Res., 40, 123-127 (2000).
13. Hoffman, A. and Stepensky, D., Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit. Rev. Ther. Drug Carrier Syst., 16, 571-639 (1999).
14. Hooper, W. D., Kavanagh, M. C., Herkes, G. K., and Eadie, M. J., Lack of a pharmacokinetic interaction between phenobarbitone and gabapentin. Br. J. Clin. Pharmacol., 31, 171-174 (1991).
15. Ifa, D. R., Falci, M., Moraes, M. E., Bezerra, F. A., Moraes, M. O., and de Nucci, G., Gabapentin quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequivalence study. J. Mass Spectrom., 36, 188-194 (2001).
16. Ishibashi, T., Hatano, H., Kobayashi, M., Mizobe, M., and Yoshino, H., In vivo drug release behavior in dogs from a new colon-targeted delivery system. J. Control. Release, 57, 45-53 (1999a).
17. Ishibashi, T., Ikegami, K., Kubo, H., Kobayashi, M., Mizobe, M., and Yoshino, H., Evaluation of colonic absorbability of drugs in dogs using a novel colon-targeted delivery capsule (CTDC). J. Control. Release, 59, 361-376 (1999b).
18. Fix, J. A., Cargill, R., and Engle, K., Controlled gastric emptying. III. Gastric residence time of a nondisintegrating geometric shape in human volunteers. Pharm. Res., 10, 1087-1089 (1993).
19. Kaniwa, N., Aoyagi, N., Ogata, H., and Ejima, A., Gastric emptying rate of drug preparations. I. Effect of size of dosage, forms, foods and species on gastric emptying rate. J. Pharmacobio-Dyn., 11, 563-570 (1988).
20. Karttunen, P., Uusitupa, M., and Lamminsivu, U., The pharmacokinetics of metformin: a comparison of the properties of a rapid-release and a sustained-release preparation. Int. J. Clin. Pharmacol. Ther. Toxicol., 21, 31-36 (1983).
21. Kedzierewicz, F., Thouvenot, P., Lemut, J., Etienne, A., Hoffman, M., and Maincent, P., Evaluation of peroral silicone dosage forms in humans by gamma-scintigraphy. J. Control. Release, 58, 195-205 (1999).
22. Klausner, E. A., Lavy, E., Stepensky, D., Friedman, M., and Hoffman, A., Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm. Res., 19, 1516-1523 (2002).
23. Klausner, E. A., Eyal, S., Lavy, E., Friedman, M., and Hoffman, A., Novel levodopa gastroretentive dosage form: in-vivo evaluation in dogs. J. Control. Release, 88, 117-126 (2003a).
24. Klausner, E. A., Lavy, E., Barta, M., Cserepes, E., Friedman, M., and Hoffman, A., Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm. Res., 20, 1466-1473 (2003b).
25. Kriel, R. L., Birnbaum, A. K., Cloyd, J. C., Ricker, B. J., Jones, Saete, C., and Caruso, K. J., Failure of absorption of gabapentin after rectal administration. Epilepsia, 38, 1242-1244 (1997).
26. Lehr, C. M., Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug Carrier Syst., 11, 119-160 (1994).
27. Noel, M., Kinetic study of normal and sustained dosage forms of metformin in normal subjects. Res. Clin. Forums, 1, 35-50 (1979).
28. Owen, S. C., Polyethylene Oxide. In Handbook of Pharmaceutical Excipients (5th), Rowe, R. C., Sheskey, P. J. and Owen, S. C., (Eds). American Pharmacists Association: Washington, The Pharmaceutical Press, Royal Pharmaceutical Society of Great Britain: London, (2005).
29. Park, H. M., Chernish, J. M., Rosenbeck, B. D., Brunelle, R. L., Hargrove, B., and Wellman, H. N., Gastric emptying of enteric coated tablets. Dig. Dis. Sci., 29, 207-212 (1984).
30. Pentikainen, P. J., Bioavailability of metformin. Comparison of solution, rapidly dissolving tablet and three sustained-release products. Int. J. Clin. Pharmacol. Ther. Toxicol., 24, 213-220 (1986).
31. Ponchel, G. and Irache, J. M., Specific and non-specific bioadhesive particulate systems for oral delivery to the gastrointestinal tract. Adv. Drug Del. Rev., 34, 191-219 (1998).
32. Richter, A., Anton, S. E., Koch, P., and Dennett, S. L., The impact of reducing dose frequency on health outcomes. Clin. Ther., 25, 2307-2335 (2003).
33. Singh, B. N. and Kim, K. H., Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J. Control. Release, 63, 235-259 (2000).
34. Stepensky, D., Friedman, M., Srour, W., Raz, I., and Hoffman, A., Preclinical evaluation of pharmacokinetic-pharmacodynamic rationale for oral CR metformin formulation. J. Control. Release, 71, 107-115 (2001).
35. Stevenson, C. M., Kim, J., and Fleisher, D., Colonic absorption of antiepileptic agents. Epilepsia, 38, 63-67 (1997).
36. Stewart, B. H., Kugler, A. R., Thompson, P. R., and Bockbrader, H. N., A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of the lack of proportionality between increasing dose and drug levels in plasma. Pharm. Res., 10, 276-281 (1993).
37. Talukder, R. and Fassihi, R., Gastroretentive delivery systems: a mini review. Drug Dev. Ind. Pharm., 30, 1019-1028 (2004).
38. Uchino, H., Kanai, Y., Kim, D. K., Wempe, M. F., Chairoungdua, A., Morimoto, E., Anders, M. W., and Endou, H., Transport of amino acid-releated compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition. Mol. Pharmacol., 61, 729-737 (2002).
39. Vollmer, K. O., Anhut, H., Thomann, P., Wagner, F., and Jahnchen, D., Pharmacokinetics model and absolute bioavailability of new anticonvulsant gabapentin. Adv. Epileptol., 17, 209-211 (1989).